Literature DB >> 29741220

NHL in adolescents and young adults: A unique population.

Jessica Hochberg1, Allyson Flower1,2, Laurence Brugieres3, Mitchell S Cairo1,2,4,5,6.   

Abstract

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of lymphoid malignancies with high incidence in adolescents and young adults (AYAs). The most common diseases include diffuse large B-cell lymphoma, anaplastic large cell lymphoma, Burkitt lymphoma, lymphoblastic lymphoma, and primary mediastinal large B-cell lymphoma. In comparison to younger children and adults, AYAs (15-39 years) with NHL present a specific set of challenges including variations in tumor biology, inconsistent treatment, pharmacodynamics, and psychosocial barriers. While survival of AYAs with NHL has improved, cure rates remain suboptimal. Incorporation of novel agents into pediatric-inspired treatment regimens specifically designed for NHL in AYAs has led to improved outcomes. Consideration of AYAs as a distinct population in the diagnosis and treatment of NHL is encouraged.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  B-cell NHL; adolescents; hematology/oncology; lymphoblastic lymphoma; non-Hodgkin lymphoma; young adults

Mesh:

Year:  2018        PMID: 29741220     DOI: 10.1002/pbc.27073

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

Review 1.  Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives.

Authors:  Mitchell S Cairo; Auke Beishuizen
Journal:  Br J Haematol       Date:  2019-02-06       Impact factor: 6.998

2.  Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.

Authors:  Jinqiu Guan; Feifei Sun; Juan Wang; Zijun Zhen; Xiaofei Sun; Yizhuo Zhang; Junting Huang; Suying Lu; Jia Zhu; Xiaoqin Zhu; Huiqiang Huang; Zhongjun Xia; Yi Que; Ruiqing Cai
Journal:  Ann Hematol       Date:  2022-01-08       Impact factor: 3.673

3.  Racial and ethnic differences in diffuse large B-cell lymphoma survival among an underserved, urban population.

Authors:  Deanna Blansky; Melissa Fazzari; Ioannis Mantzaris; Thomas Rohan; H Dean Hosgood
Journal:  Leuk Lymphoma       Date:  2020-10-28

Review 4.  Cancer incidence and mortality trends in young adults in Metropolitan Lima young adults, 1990-2012.

Authors:  Jorge Luna-Abanto; Luis García Ruiz; Jheff Laura-Martinez; Tessy Tairo-Cerron
Journal:  Ecancermedicalscience       Date:  2020-04-20

Review 5.  The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL).

Authors:  Yaya Chu; Margaret Lamb; Mitchell S Cairo; Dean A Lee
Journal:  Curr Treat Options Oncol       Date:  2022-03-08

6.  Bone damage after chemotherapy for lymphoma: a real-world experience.

Authors:  S Mancuso; Dalila Scaturro; M Santoro; G Di Gaetano; F Vitagliani; V Falco; S Siragusa; S Gonnelli; G Letizia Mauro
Journal:  BMC Musculoskelet Disord       Date:  2021-12-07       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.